www.chiesigroup.com Guest

2009 was the first complete financial year of Chiesi’s direct presence in China through Chiesi Pharmaceuticals (Shanghai) Co. Ltd.

Currently, the company is focusing on promoting Curosurf to maintain its leading market position. Meanwhile, the Regulatory Affairs Department deals with the Drug Registration Process for three of Chiesi’s respiratory products, including Foster, due for launch in 2012.

Curosurf sales exceeded last year’s by 25%, continuing proof of growth in the Chinese market. Chiesi expanded its field force allowing coverage of more geographic area and more hospitals.

Furthermore, it has continued to play a fundamental role for neonatology in China.

It has done so through the promotion of a targeted marketing program which involved the National Curosurf VIP Meeting, the sponsorship of opinion leaders at the Curosurf Family Meeting, and a series symposiums and workshops at the regional level. The product has become the “Golden Standard” treatment for neonatal Respiratory Distress Syndrome in China. The affiliate re-acquired rights to sales of Vasobral in China from its former partner.

The objectives for the year include growth of Curosurf sales maintaining market share at 85%, re-launch of Vasobral, with an expected growth rate of 20%.